Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers November 17, 2017
Pharmacy Choice - News - Pharmaceutical Industry Trends and Policy - November 17, 2017

Pharmacy News

 Pharmaceutical Industry Trends and Policy
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

11/17/17 - "Conotoxin Polypeptide K-Cptx-Bt102, and Method for Preparation Threof and Application Thereof" in Patent Application Approval Process (USPTO...
"Conotoxin Polypeptide K-Cptx-Bt102, and Method for Preparation Threof and Application Thereof" in Patent Application Approval Process. By a News Reporter-Staff News Editor at Drug Week A patent application by the inventors Lin, Zhilong; Wen, Bo; Tong, Ting; Liu, Jie; Du, Chaoqin; Mo, Fen; Peng, Chao; Shi, Qiong, filed on September 30, 2014, was
11/17/17 - "Method of Identifying Risk for Thyroid Disorder" in Patent Application Approval Process (USPTO 20170307629)
By a News Reporter-Staff News Editor at Drug Week A patent application by the inventor Margolin, David H., filed on May 10, 2017, was made available online on November 2, 2017, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application is assigned to Genzyme Corporation. The following quote wa
11/17/17 - "New Indication of Cardiovascular Drugs for Preparation of Cancer Inhibition Pharmaceutical Composition" in Patent Application Approval Process...
"New Indication of Cardiovascular Drugs for Preparation of Cancer Inhibition Pharmaceutical Composition" in Patent Application Approval Process. By a News Reporter-Staff News Editor at Drug Week A patent application by the inventors Chen, Chiu-Hung; Chuang, Show-Mei; Hsiao, Nai-Wan; Liang, Ruei-Yue; Tan, Xiao-Tong, filed on October 23, 2015, was
11/17/17 - /C O R R E C T I O N Caligor Holdco, LLC/
In the news release, Caligor Holdco, LLC, Leader in Strategic Clinical Trial Services, Acquires The Coghlan Group, issued 16- Nov-2017 by Caligor Holdco, LLC over PR Newswire, we are advised by the company that there have been multiple changes. Caligor Rx, Leader in Strategic Clinical Trial Services, Acquires The Coghlan Group. SECAUCUS, New Jersey
11/17/17 - 44 state AGs ask Congress to repeal law favoring drug companies
-Attorneys general from 44 states on Tuesday signed a letter asking Congress to repeal the Ensuring Patient Access and Effective Drug Enforcement Act, which they claim prevents the Drug Enforcement Agency from using effective drug enforcement efforts. The National Association of Attorneys General sent the letter to Republican and Democratic leaders
11/17/17 - AbbVie to Present at the Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference
NORTH CHICAGO- AbbVie will participate in the Evercore ISI Biopharma Catalyst/Deep Dive Conference on Wednesday, November 29, 2017. AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world's most complex and critical conditions. In more than 75 countries, AbbVie employ
11/17/17 - Acceleron Announces Preclinical Results in Pulmonary Arterial Hypertension at the American Heart Association 2017 Scientific Sessions
CAMBRIDGE, Mass.- Acceleron Pharma Inc., a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced new preclinical results with sotatercept in pulmonary arterial hypertension during an oral presentation at the American Heart Association 2017 Scientific Sessions.
11/17/17 - Achieve Announces Results of Clinical Study Demonstrating Similar Bioavailability of Cytisine in Fed and Fasted Subjects
BOTHELL, Wash and VANCOUVER, British Columbia- Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced results of a clinical study evaluating the effect of food on the bioavailability of 3 mg cytisine. Additionally, in preparati
11/17/17 - Achillion Reports Preliminary Proof-of-Concept With ACH-4471 for the Treatment of C3G
NEW HAVEN- Achillion Pharmaceuticals, Inc. today reported preliminary proof-of-concept results from group 1 of its ongoing Phase 2, open-label, 14- day study of ACH-4471 for patients with C3 glomerulopathy or immune complex-mediated membranoproliferative glomerulonephritis. Tom Barbour, Royal Melbourne Hospital, Melbourne, Australia, Department of.
11/17/17 - Acorda to Present at the Stifel 2017 Healthcare Conference
By a News Reporter-Staff News Editor at Drug Week Acorda Therapeutics, Inc. announced that Ron Cohen, M.D., Acorda's President and CEO, will present at the Stifel Healthcare Conference in New York on Wednesday, November 15, 2017 at 10:45 a.m. ET. A live audio webcast of the presentation can be accessed under "Investor Events" in the Investor sect
11/17/17 - Advanced Accelerator Applications Reports 39% Sales Growth for Third Quarter 2017
Advanced Accelerator Applications S.A., a leader in nuclear medicine theragnostics, today announced its financial results for the third quarter ended September 30, 2017. Stefano Buono, Chief Executive Officer of AAA, commented, The last few months have been truly transformative for AAA. We are progressing with the commercial launch of lutetium
11/17/17 - Advanced Medical Isotope Corporation (ADMD) Refines Strategy to Accelerate Penetration of Veterinary Market
Advanced Medical Isotope Corporation, a late-stage radiation oncology-focused medical device company, is initially focusing its animal therapy development efforts on canine soft-tissue sarcomas and feline sarcomas; which the Company believes will establish a short-term pathway to market for its RadioGel? product in the veterinary services indus
11/17/17 - Agency Information Collection Activities; Proposed Collection; Comment Request; Generic Clearance for the Collection of Qualitative Data on Tobacco Products and Communications
Under the Paperwork Reduction Act of 1995, Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the Gen
11/17/17 - Agios Presents Updated Phase 1 Data from Dose Expansion Cohort of Ivosidenib (AG-120) in Patients with IDH1 Mutant Positive Glioma
Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today presented updated data from the dose expansion cohort of the Phase 1 study evaluating single agent ivosidenib in patients with progressive low grade isocitrate dehydrogenase-1 mutant glioma. The data were presented today in a
11/17/17 - Alkermes - VIVITROL and Value of Medication-Assisted Treatment for Opioid Dependence Featured in Study Sponsored by National Institute on Drug Abuse
DUBLIN- Results from a National Institute on Drug Abuse- funded study, were published in The Lancet today, comparing extended-release naltrexone and buprenorphine-naloxone, two options for opioid dependence. This is the second study published in the past month comparing these two medications and it provides additional evidence supporting the use of
11/17/17 - Allergan Receives Approval for Ozurdex Dexamethasone Intravitreal Implant 0.7 mg in China for the Treatment of Retinal Vein Occlusion RVO
By a News Reporter-Staff News Editor at Health& Medicine Week Allergan plc announced that it has received an Imported Drugs License from the Chinese Food and Drug Administration to market Ozurdex for the treatment of adult patients with macular edema following either Branch Retinal Vein Occlusion or Central Retinal Vein Occlusion.
11/17/17 - Alnylam Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis [Tehran Times (Iran)]
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, today announced the company has initiated submission of a rolling New Drug Application to the U.S. Food and Drug Administration for patisiran, an investigational RNAi therapeutic targeting transthyretin, for the treatment of hereditary ATTR amyloidosis. The rolling submission all
11/17/17 - Amgen And Novartis Announce Expanded Collaboration With Banner Alzheimer's Institute In Pioneering Prevention Program
By a News Reporter-Staff News Editor at Health& Medicine Week Amgen and Novartis announced an expanded collaboration with the Banner Alzheimer's Institute to initiate a new trial- the Alzheimer's Prevention Initiative Generation Study 2. "As a leader in the challenging fight to unlock the biology of serious illnesses like Alzheimer's disease, we
11/17/17 - Arcturus Therapeutics Announces Completion of Merger with Alcobra Ltd. and Commences Trading on the Nasdaq Global Market [Ghana News Agency]
-Arcturus Therapeutics Ltd., a leading RNA medicines company, announced today the completion of its previously announced merger with Alcobra Ltd., effective as of November 15, 2017. Pursuant to the merger, the holders of shares of Arcturus Therapeutics common stock outstanding immediately prior to the merger received 0.293 shares of Alcobra ordinar
11/17/17 - Array BioPharma Inc. (NASDAQ:ARRY) Files An 8-K Entry into a Material Definitive Agreement
Array BioPharma Inc. (NASDAQ:ARRY) Files An 8-K Entry into a Material Definitive AgreementItem 8.01 Entry into a Material Definitive Agreement. Exchange Agreements On November16, 2017, Array BioPharma entered into separate, privately negotiated exchange agreements (the Exchange Agreements) with a limited number of holders (Noteholders)
11/17/17 - Array Biopharma Inc. Files SEC Form 10-Q, Quarterly Report [Sections 13 Or 15(D)]: (Oct. 31, 2017)
By a News Reporter-Staff News Editor at Drug Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Array Biopharma Inc. was posted on October 31, 2017. The SEC file number is 0001100412-17-000009.. A U.S. Securities and Exchange Commission filing is a formal
11/17/17 - Array Biopharma Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities: (Oct. 27, 2017)
By a News Reporter-Staff News Editor at Drug Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Array Biopharma Inc. was posted on October 27, 2017. The SEC file number is 0001562180-17-003341.. A U.S. Securities and Exchange Commission filing is a formal
11/17/17 - Array Biopharma Inc. Files SEC Form 8-K, Current Report: (Oct. 27, 2017)
By a News Reporter-Staff News Editor at Drug Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Array Biopharma Inc. was posted on October 27, 2017. The SEC file number is 0001104659-17-064397.. A U.S. Securities and Exchange Commission filing is a formal
11/17/17 - Array Biopharma Inc. Files SEC Form 8-K, Current Report: (Oct. 31, 2017)
By a News Reporter-Staff News Editor at Drug Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Array Biopharma Inc. was posted on October 31, 2017. The SEC file number is 0001144204-17-054985.. A U.S. Securities and Exchange Commission filing is a formal
11/17/17 - AstraZeneca - FASLODEX receives US FDA approval for the treatment of advanced breast cancer in combination with abemaciclib
AstraZeneca today announced that the US Food and Drug Administration has approved a new indication for FASLODEX, expanding the indication to include use with abemaciclib, a CDK4/6 inhibitor, for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2 negative advanced or metastatic breast cancer in women with disease...
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415